ELEV - Elevation Oncology, Inc. Forward P/S Multiple
Elevation Oncology relies on a strong staff of molecular biologists incentivized by stock options. On the GURU.Markets platform, the expected price-to-sales ratio demonstrates asset dynamics, where the indicator signals the trend status. Growth potential is based on the development of precision medicines and grants, while business security is ensured by strict FDA oversight and unique patents for tumor therapy.
Analytical breakdowns for elevationoncology.com (ELEV)
- market price and analyst price targets:
- market capitalization statistics:
- issuer book value statistics:
- debt and liquidity data:
Total Debt to Equity Ratio Elevation Oncology|ELEV - Long-Term Loans to Capital Ratio|Short-Term Debt to Capital Elevation Oncology, Inc.|ELEV - Company Total Debt Obligations|Debt to Book Capitalization Ratio Elevation Oncology, Inc.|ELEV - Long-Term Debt|Company Short-Term Debt Elevation Oncology|Quick Liquidity Indicator elevationoncology.com
- net income and valuation multiples indicators:
ELEV - Final Profit|Expected Profit Elevation Oncology|ELEV - Market Cap to Earnings|Future Price to Earnings Elevation Oncology|ELEV - Growth-Adjusted P/E Ratio|EV/EBITDA Multiple Elevation Oncology, Inc.|ELEV - Operating profit before deduction of amortization|Earnings per share for the last twelve months Elevation Oncology|ELEV - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months elevationoncology.com|ELEV - Earnings per share growth in current year|Net earnings per share growth forecast for next year Elevation Oncology
- sales revenue and business income indicators:
Comprehensive company analysis:ELEV (Elevation Oncology)
For the biotech sector, where the development of the ADC drug EO-3021 determines the valuation of Elevation Oncology (ELEV), calculating the ratio of market capitalization to expected sales allows for an assessment of the premium for future success. By analyzing the current forward P/S level, an investor determines the asset's margin of safety: a decline in this metric may signal either an emerging entry point or a market reassessment of the therapy's commercialization potential.
Competitor analysis
Price-to-Projected Revenue Ratio BeiGene ONC|Halozyme Therapeutics, Inc. - Price-to-Projected Revenue Ratio|RevMed - Forward P/S Multiple|Market Cap to Future Revenue Ratio Ascentage Pharma Corp|CGON (CG Oncology, Inc.) - Forward Price-to-Revenue Multiple|URGN (urogen.com) - Price-to-Projected Revenue Ratio|BCAX (Bicara Therapeutics) - Forward P/S Multiple|Forward P/S Multiple Personalis Inc|Forward Price-to-Revenue Multiple ERAS (Erasca Corp)|Price to Expected Revenue Ratio DCTH|Forward P/S Multiple YMAB (Y-mAbs Therapeutics)|Market Cap to Expected Sales Ratio aurabiosciences.com (AURA)|CADL - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Accuray Inc|sellaslifesciences.com (SLS) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue ACTU|Forward Price-to-Revenue Multiple CTOR|HURA: Forward Price to Sales|Price-to-Projected Revenue Ratio Protara Therapeutics, Inc. (TARA)|FATE - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio Aadi Bioscience WHWK|TCRX: Market Cap to Projected Revenue|Champions Oncology Corp - Forward P/S Multiple|XBiotech Inc. (XBIT) - Forward Price-to-Revenue Multiple|cel-sci.com (CVM) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio OS Therapies Inc. (OSTX)|Price-to-Projected Revenue Ratio Radiopharm Theranostics Limited|Price-to-Projected Revenue Ratio ARTV|Price-to-Projected Revenue Ratio Adlai Nortye Ltd. (ANL)|VERU - Market Cap to Future Revenue Ratio|Forward P/S Multiple TPST (Tempest Therapeutics, Inc.)|Projected Price to Revenue Xilio Therapeutics Inc|RENB: Forward Price-to-Revenue Multiple|Market Cap to Future Revenue Ratio Mural Oncology plc|KAPA: Forward P/S Multiple|Market Cap to Future Revenue Ratio OnKure Therapeutics (OKUR)|Price-to-Projected Revenue Ratio CytoMed Therapeutics Ltd|Price-to-Projected Revenue Ratio CRIS|Forward P/S Multiple APLM|THAR - Market Cap to Future Revenue Ratio|Advanced Biomed - Forward Price-to-Revenue Multiple|genprex.com - Price-to-Projected Revenue Ratio|Calidi Bio - Forward P/S Multiple|Sunshine Biopharma Inc. (SBFM) - Forward Price-to-Revenue Multiple|XBIO: Forward P/S Multiple|Salarius Pharma (SLRX) - Forward P/S Multiple|Price-to-Projected Revenue Ratio Purple Biotech|Market Cap to Projected Revenue AONC (AON)|Forward P/S Multiple BGNE|Forward Price-to-Revenue Multiple Checkpoint Therapeutics Inc. CKPT|Forward P/S Multiple ICAD (iCAD)|Ikena Oncology Inc. (IKNA) - Market Cap to Future Revenue Ratio|NTBL - Price-to-Projected Revenue Ratio|Forward Price to Sales VIRX (Viracta Therapeutics)|MOR (MorphoSys) - Forward Price-to-Revenue Multiple|NAYA Biosciences Inc - Forward Price to Sales|AAPGV (Ascentage Pharma Group Ltd) - Forward P/S Multiple
